Table 1.
Pro-myelinating compounds in ongoing clinical trials for multiple sclerosis (MS) treatment. Semaphorin-4D (SEMA4D); progressive MS (PMS); relapsing-remitting MS (RRMS); secondary progressive MS (SPMS); leucine-rich repeat.
| Compound | Classification | Mechanism of Action | Indication | Clinical Trial | References |
|---|---|---|---|---|---|
|
Antisemaphorine 4D (VX15/2503) Catalent Pharma Solutions© |
Humanizes monoclonal antibody | anti-SEMA4D. Blocks the interaction between SEMA4D and its receptors |
PMS; RRMS | Phase I | [57] |
|
Liothyronine (L-T3 liothyronine sodium) |
Nuclear Hormone Agonists | Thyroid receptor agonist | MS | Phase I | [58] |
|
rHIgM22 Acorda Therapeutics, Inc.© |
Human IgM antibody | Not clarified | MS | Phase I | [59] |
| Domperidone | D2/D3 dopamine receptor antagonist | Increases prolactin serum levels | SPMS | Phase II | [60] |
|
Clemastine (Clematine fumate meclastin) |
Antihistamine | H1 antihistamine antagonist M1/M3 muscarinic receptors reverse antagonist |
RRMS | Phase II | [61,62] |
|
GSK239512 GlaxoSmithKline© |
Antihistamine | H3 receptor antagonist | RRMS | Phase II | [63] |